DALLAS, Sept. 8, 2011 (GLOBE NEWSWIRE) -- The American Heart Association notes the FDA advisory committee’s recommendation today to give market approval for rivaroxaban, an oral anticoagulant drug, for the prevention of stroke and blood clots in patients with atrial fibrillation.
